Literature DB >> 28052348

Aspirin use and risk of cholangiocarcinoma: External validation with big data.

Haider Altaii1, Sadeer G Al-Kindi2, Guilherme H Oliveira2, Zaid Yaqoob3, Carlos Romero-Marrero4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28052348     DOI： 10.1002/hep.28920

Source DB:  PubMed          Journal:  Hepatology        ISSN： 0270-9139            Impact factor:   17.425


× No keyword cloud information.
  4 in total

1.  Association Between Aspirin and Cholangiocarcinoma in a Large Asian Cohort.

Authors:  Min-Hyung Kim; Sang Min Park; Jooyoung Chang; In Cheol Hwang
Journal:  JAMA Oncol       Date:  2020-12-01       Impact factor: 31.777

2.  Epidemiology of neuroendocrine tumors of the appendix in the USA: a population-based national study (2014-2019).

Authors:  Motasem Alkhayyat; Mohannad Abou Saleh; Wendy Coronado; Mohammad Abureesh; Mohammad Zmaili; Thabet Qapaja; Ashraf Almomani; George Khoudari; Emad Mansoor; Gregory Cooper
Journal:  Ann Gastroenterol       Date:  2021-06-14

3.  Aspirin use is associated with a reduced risk of cholangiocarcinoma: a systematic review and meta-analysis.

Authors:  Jianping Xiong; Weiyu Xu; Jin Bian; Hanchun Huang; Yi Bai; Yiyao Xu; Xin Lu; Haitao Zhao
Journal:  Cancer Manag Res       Date:  2018-10-01       Impact factor: 3.989

4.  Annexin10 promotes extrahepatic cholangiocarcinoma metastasis by facilitating EMT via PLA2G4A/PGE2/STAT3 pathway.

Authors:  Rongqi Sun; Zengli Liu; Bo Qiu; Tianli Chen; Zhipeng Li; Xiaoming Zhang; Yunfei Xu; Zongli Zhang
Journal:  EBioMedicine       Date:  2019-09-03       Impact factor: 8.143
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.